Cytochrome P-450 3A: interactions with dermatologic therapies.
Recent case reports and studies suggest that interactions involving the cytochrome P-450 mixed function oxidase system are important causes of medication toxicity and decreased efficacy during combination drug therapy. The cytochrome P-450 3A3/4 isoenzyme is involved in many significant drug interactions. New and familiar drugs continue to be implicated as having potentially serious interactions with this group of enzymes. An understanding of the basic principles of these interactions may have a major impact on patient outcome.
Singer
M I
MI
Division of Clinical Pharmacology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
Shapiro
L E
LE
Shear
N H
NH
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000927:Anticonvulsants / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology; D001189:Aryl Hydrocarbon Hydroxylases; D001393:Azoles / Q000494:pharmacology; D001667:Binding, Competitive; D002957:Citrus; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism / Q000494:pharmacology*; D003879:Dermatologic Agents / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D018942:Macrolides; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D012871:Skin Diseases / Q000188:drug therapy*; D013379:Substrate Specificity
D000900:Anti-Bacterial Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D000935:Antifungal Agents; D000995:Antitubercular Agents; D001393:Azoles; D065607:Cytochrome P-450 Enzyme Inhibitors; D003879:Dermatologic Agents; D018942:Macrolides; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating